1/4
| 2/4 | Liver Enzymes Information | 3/4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Welcome to my compendium website
on Liver Enzymes.
This site will give you a lot of information
helpful to learn about your liver. My liver is not
doing what it should. I am on my 2nd round of a bout with cancer. It
started as a tumor in my parotid gland. ( Read details at
www.IamFightingCancer.com )
6 months ago I developed a significant cough. Finally after a couple of months it was determined that my Parotid Gland tumor that was gone had metastiszed showing up in my left lung. After a chemo scheduled every 3 weeks it was re-scheduled to a weekly infusion to lessen the side effects. One of the side effects was depression for which I was prescribed a prescription of the generic sertraline, 50 mg. which is better known as Zoloft. It was determined that my blood tests showed that my liver enzymes were 10 times what they should be. WOW. One of the possible causes was the DOCETAIL chemotherapy. Dr. G. stopped the chemo but continued on with the herceptin for HER2 Another blood test was taken. Now the bad count in the blood had not improved but had gotten worse than before. YUK. WHAT IS CAUSING MY LIVER TO PRODUCE TOO MANY ENZYMES.
The new experiment would be to
cut off the only pill I am taking which would be the Zoloft or Sertraline,
50 mg. A week later blood test showed that the enzyme count was down but
the count was still bad enough to prevent any type of serving of the standard
chemo. Dr. G felt it was the Zoloft because cutting it down improve the liver
function. Today1-25-07 I will take the Herceptin infusion and not any chemo for
2 more weeks to see if the blood will return to more reasonable level. As I
research more about the causes of liver damage for my own use, I
will document them below to better enhance your personal awareness of the
problem.
Directory of Video Sites
Directory of Sites
You are at:
http://www.NewMedicalDirectories.com/Liver-Enzymes/Information.html
ud
08/29/2009 05:05 PM -0500
Bookmark
this page now!
The liver is an
organ in some
animals,
including
mammals (and therefore humans),
birds, and
reptiles.
It plays a major role in
metabolism and has a number of
functions in the body including
glycogen
storage,
plasma protein synthesis, and drug detoxification. This organ also is
the largest
gland in the
human body. It produces
bile, which
is important in
digestion. It performs and regulates a wide variety of high-volume
biochemical reactions requiring specialized
tissues. Medical terms related to the liver often start in hepato-
or hepatic from the
Greek word for liver, hepar. [hide] The adult human liver normally weighs between 1.3
- 3.0
kilograms, and it is a soft, pinkish-brown "boomerang
shaped" organ. It is the second
largest organ (the largest organ being the
skin) and the
largest gland within the human body. It is located on the right side of the upper
abdomen body
diaphragm. The liver lies on the right of the stomach and makes a kind
of bed for the
gallbladder (which stores
bile). The
splenic vein, joining with the
superior mesenteric vein to form the
portal vein, brings venous
blood from
the spleen,
pancreas,
small intestine, and
large intestine, so that the liver can process the
nutrients and byproducts of food digestion. The
hepatic veins drain directly into the
inferior vena cava. The
hepatic artery is generally a branch from the
celiac trunk, although occasionally some or all of the blood can be
from other branches such as the
superior mesenteric artery. Approximately ⅔ of the blood flow to the liver is
from the portal venous system, and ⅓ is from the hepatic artery. The
bile produced
in the liver is collected in
bile canaliculi, which merge to form bile ducts. These eventually drain into the right and left
hepatic ducts, which in turn merge to form the
common hepatic duct. The
cystic duct (from the
gallbladder) joins with the
common hepatic duct to form the
common bile duct. Bile can either drain directly into the
duodenum
via the
common bile duct or be temporarily stored in the
gallbladder via the cystic duct. The
common bile duct and the
pancreatic duct enter the
duodenum
together at the
ampulla of Vater. The branchings of the
bile
ducts resemble those of a tree, and indeed the term "biliary
tree" is commonly used in this setting. The liver is among the few internal human organs
capable of natural
regeneration of lost
tissue; as little as 25% of remaining liver can regenerate into a
whole liver again. This is predominantly due to the
hepatocytes acting as unipotential
stem
cells (i.e. a single
hepatocyte can divide into two
hepatocyte daughter cells). There is also some evidence of
bipotential
stem
cells, called
oval cells, which can differentiate into either
hepatocytes or
cholangiocytes (cells that line the
bile
ducts). Apart from a patch where it connects to the
diaphragm, the liver is covered entirely by
visceral
peritoneum, a thin, double-layered
membrane that reduces
friction
against other organs. The
peritoneum folds back on itself to form the
falciform ligament and the
right and
left triangular ligaments. These "ligaments"
are in no way related to the true
anatomic ligaments in
joints,
and have essentially no functional importance, but they are easily
recognizable surface landmarks. Traditional gross anatomy divided the
liver into four
lobes based on surface features. The
falciform ligament is visible on the front (anterior
side) of the liver. This divides the liver into a
left anatomical lobe, and a
right anatomical lobe. If the liver is flipped over, to look at it from
behind (the
visceral
surface), there are two additional lobes between the right and left. These
are the
caudate lobe (the more
superior),
and below this the
quadrate lobe. From behind, the lobes are divided up by the
ligamentum venosum and
ligamentum teres (anything left of these is the left lobe), the
transverse fissure (or
porta hepatis) divides the
caudate
from the
quadrate lobe, and the right
sagittal fossa, which the
inferior vena cava runs over, separates these two lobes from the right
lobe. For purposes such as advanced liver surgery, it
is crucial to understand the fundamental importance of the liver on the
blood supply and biliary drainage system. The central area where the
common bile duct,
portal vein, and
hepatic artery enter the liver is the
hilum or "porta
hepatis". The duct, vein, and artery divide into left and right
branches, and the portions of the liver supplied by these branches
constitute the functional left and right lobes. The functional lobes are separated by a plane
joining the gallbladder fossa to the inferior vena cava. This separates
the liver into the true right and left lobes. The middle hepatic vein also
demarcates the true right and left lobes. The right lobe is further
divided into an
anterior
and
posterior segment by the right hepatic vein. The left lobe is divided
into the
medial and
lateral
segments by the left hepatic vein. The fissure for the
ligamentum teres (the ligamentum teres becomes the falciform ligament)
also separates the medial and lateral segmants. The medial segment is what
used to be called the
quadrate lobe. In the widely used Couinaud or "French" system, the
functional lobes are further divided into a total of eight subsegments
based on a transverse plane through the bifurcation of the main portal
vein. The
caudate lobe is a separate structure which receives blood flow from
both the right- and left-sided vascular branches.[2][3]
The subsegments corresponding to the anatomical lobes are as follows: Each number in the list corresponds to one in the
table. The various functions of the liver are carried
out by the liver cells or
hepatocytes. Currently, there is no artificial organ or device
capable of emulating all the functions of the liver. Some functions can be
emulated by
liver dialysis, an experimental treatment for
liver failure. Many diseases of the liver are accompanied by
jaundice
caused by increased levels of
bilirubin in the system. The bilirubin results from the breakup of the
hemoglobin of dead
red blood cells; normally, the liver removes bilirubin from the blood
and excretes it through bile. There are also many pediatric liver disease,
including
biliary atresia,
alpha-1 antitrypsin deficiency,
alagille syndrome, and
progressive familial intrahepatic cholestasis, to name but a few. A number of
liver function tests are available to test the proper function of the
liver. These test for the presence of enzymes in blood that are normally
most abundant in liver tissue, metabolites or products. Human liver transplant was first performed by
Thomas Starzl in USA and Roy Calne in England in 1963 and 1965
respectively.
Liver transplantation is the only option for those with irreversible
liver failure. Most transplants are done for chronic liver diseases
leading to
cirrhosis, such as chronic hepatitis C, alcoholism, autoimmune
hepatitis, and many others. Less commonly, liver transplantation is done
for
fulminant hepatic failure, in which liver failure occurs over days to
weeks. Liver
allografts for
transplant usually come from non-living donors who have died from
fatal brain injury.
Living donor liver transplantation is a technique in which a portion
of a living person's liver is removed and used to replace the entire liver
of the recipient. This was first performed in
1989 for
pediatric liver transplantation. Only 20% of an adult's liver (Couinaud
segments 2 and 3) is needed to serve as a liver allograft for an infant or
small child. More recently, adult-to-adult liver
transplantation has been done using the donor's right hepatic lobe which
amounts to 60% of the liver. Due to the ability of the liver to
regenerate, both the donor and recipient end up with normal liver
function if all goes well. This procedure is more controversial as it
entails performing a much larger operation on the donor, and indeed there
have been at least 2 donor deaths out of the first several hundred cases.
A recent publication has addressed the problem of donor mortality, and at
least 14 cases have been found.[4]
The risk of postoperative complications (and death) is far greater in
right sided hepatectomy than left sided operations The liver develops as an
endodermal outpocketing of the
foregut called
the hepatic diverticulum. Its initial blood supply is primarily
from the
vitelline veins that drain blood from the
yolk sac.
The superior part of the hepatic diverticulum gives rise to the
hepatocytes and bile ducts, while the inferior part becomes the
gallbladder and its associated cystic duct. In the growing fetus, a major source of blood to
the liver is the
umbilical vein which supplies nutrients to the growing fetus. The
umbilical vein enters the abdomen at the umbilicus, and passes upward
along the free margin of the
falciform ligament of the liver to the inferior surface of the liver.
There it joins with the left branch of the portal vein. The
ductus venosus carries blood from the left portal vein to the left
hepatic vein and thence to the
inferior vena cava, allowing placental blood to bypass the liver. In the fetus, the liver is developing throughout
normal gestation, and does not perform the normal filtration of the infant
liver. The liver does not perform digestive processes because the fetus
does not consume meals directly, but receives nourishment from the mother
via the
placenta. The fetal liver releases some blood stem cells that migrate
to the fetal
thymus, so initially the
lymphocytes, called
T-cells,
are created from fetal liver stem cells. Once the fetus is delivered, the
formation of blood stem cells in infants shifts to the red
bone marrow. After birth, the umbilical vein and ductus
venosus are completely obliterated two to five days postpartum; the former
becomes the
ligamentum teres and the latter becomes the
ligamentum venosum. In the disease state of
cirrhosis and
portal hypertension, the umbilical vein can open up again. Liver function tests (LFTs or LFs), which include
liver enzymes, are groups of
clinical biochemistry laboratory blood assays designed to give information
about the state of a patient's
liver. Most
liver diseases cause only mild symptoms initially, while it is vital that
these diseases be detected early. Hepatic involvement in some diseases can be
of crucial importance. This testing is performed by a
Medical technologist on a patient's serum or plasma which is collected by
a
phlebotomist. [hide] The liver produces most of the
plasma
proteins in the body making a measure of the amount of protein in the
blood useful. Reference range (60-80 g/L).
Albumin is
a protein made specifically by the liver, and can be measured cheaply and
easily. It is the main constituent of total protein; the remaining fraction is
called
globulin (including e.g. the
immunoglobulins). Albumin levels are decreased in chronic liver disease,
such as
cirrhosis. It is also decreased in
nephrotic syndrome, where it is lost through the urine. Poor
nutrition
or states of protein catabolism may also lead to hypoalbuminaemia. The
half-life
of albumin is approximately 20 days. Albumin is not considered to be an
especially useful marker of liver synthetic function, coagulation factors (see
below) are much more sensitive. The reference range is 30-50 g/L. (3.0-5.0 g/dL)
Alanine transaminase (ALT), also called Serum Glutamic Pyruvic
Transaminase (SGPT) or Alanine aminotransferase (ALAT) is an
enzyme
present in
hepatocytes (liver cells). When a cell is damaged, it leaks this enzyme
into the blood, where it is measured. ALT rises dramatically in acute liver
damage, such as
viral hepatitis or
paracetamol (acetaminophen) overdose. Elevations are often measured in
multiples of the upper limit of normal (ULN). The reference range is 15-45 U/L
in most laboratories.
Aspartate transaminase (AST) also called Serum Glutamic Oxaloacetic
Transaminase (SGOT) or aspartate aminotransferase (ASAT) is similar to ALT in
that it is another enzyme associated with liver parenchymal cells. It is
raised in acute liver damage, but is also present in red cells, and cardiac
and skeletal muscle and is therefore not specific to the liver. The ratio of
AST to ALT is sometimes useful in differentiating between causes of liver
damage: In resource-poor settings, the AST is more frequently
available than the ALT, because it is a cheaper assay.
Alkaline phosphatase (ALP) is an enzyme in the cells lining the
biliary ducts of the liver. ALP levels in plasma will rise with large bile
duct obstruction, intrahepatic
cholestasis or infiltrative diseases of the liver. ALP is also present in
bone and
placental
tissue, so it is higher in growing children (as their bones are being
remodelled). The reference range is usually 30-120 U/L.
Bilirubin
is a breakdown product of
heme (a part of
haemoglobin in red blood cells). The liver is responsible for clearing the
blood of bilirubin. It does this by the following mechanism: bilirubin is
taken up into
hepatocytes, conjugated (modified to make it water-soluble), and
secreted into the
bile, which is excreted into the intestine. Liver function tests typically measure Total
bilirubin (TBIL) and Direct bilirubin (a.k.a. conjugated bilirubin,
CB). Indirect bilirubin (a.k.a. unconjugated bilirubin, UCB) is
obtained by subtracting direct bilirubin from total bilirubin. Increased total bilirubin causes jaundice, and can
signal a number of problems: 1. Increased bilirubin production. This can be
due to a number of causes, including hemolytic anemias and internal
hemorrhage. 2. Problems with the liver, which are reflected as
deficiencies in bilirubin metabolism (e.g. reduced hepatocyte uptake,
impaired conjugation of bilirubin, and reduced hepatocyte secretion of
bilirubin). Some examples would be cirrhosis and viral hepatitis. 3. Obstruction of the bile ducts, reflected as
deficiencies in bilirubin excretion. (Obstruction can be located either
within the liver or outside the liver.) The diagnosis is narrowed down further by looking at
the levels of direct bilirubin. If direct (i.e. conjugated) bilirubin is
normal, then the problem is an excess of unconjugated bilirubin, and the
location of the problem is upstream of bilirubin excretion. Anemia, viral
hepatitis, or cirrhosis can be suspected. If direct bilirubin is elevated,
then the liver is conjugating bilirubin normally, but is not able to excrete
it. Bile duct obstruction by gallstones or cancer should be suspected. Although reasonably specific to the liver and a more
sensitive marker for cholestatic damage than ALP,
Gamma glutamyl transpeptidase (GGT) may be elevated with even minor,
sub-clinical levels of liver dysfunction. It can also be helpful in
identifying the cause of an isolated elevation in ALP. GGT is raised in
alcohol toxicity (acute and chronic). 5'NTD is another test specific for cholestasis or
damage to the intra or extrahepatic biliary system, and in some laboratories,
is used as a substitute for GGT for ascertaining whether an elevated ALP is of
biliary or extra-biliary origin. The liver is responsible for the production of
coagulation factors. The
international normalized ratio (INR) measures the speed of a particular
pathway of coagulation, comparing it to normal. If the INR is increased, it
means it is taking longer than usual for blood to clot. The INR will only be
increased if the liver is so damaged that synthesis of
vitamin K-dependent
coagulation factors has been impaired: it is not a sensitive measure of liver
function. It is very important to normalize the INR before
operating on people with liver problems (usually by transfusion with blood
plasma containing the deficient factors) as they could bleed excessively. The liver's ability to produce glucose (gluconeogenesis)
is usually the last function to be lost in the setting of fulminant liver
failure. Liver function tests (LFTs or LFs), which include
liver enzymes, are groups of
clinical biochemistry laboratory blood assays designed to give information
about the state of a patient's
liver. Most
liver diseases cause only mild symptoms initially, while it is vital that
these diseases be detected early. Hepatic involvement in some diseases can be
of crucial importance. This testing is performed by a
Medical technologist on a patient's serum or plasma which is collected by
a
phlebotomist. [hide]
The liver produces most of the
plasma
proteins in the body making a measure of the amount of protein in the
blood useful. Reference range (60-80 g/L).
Albumin is
a protein made specifically by the liver, and can be measured cheaply and
easily. It is the main constituent of total protein; the remaining fraction is
called
globulin (including e.g. the
immunoglobulins). Albumin levels are decreased in chronic liver disease,
such as
cirrhosis. It is also decreased in
nephrotic syndrome, where it is lost through the urine. Poor
nutrition
or states of protein catabolism may also lead to hypoalbuminaemia. The
half-life
of albumin is approximately 20 days. Albumin is not considered to be an
especially useful marker of liver synthetic function, coagulation factors (see
below) are much more sensitive. The reference range is 30-50 g/L. (3.0-5.0 g/dL)
Alanine transaminase (ALT), also called Serum Glutamic Pyruvic
Transaminase (SGPT) or Alanine aminotransferase (ALAT) is an
enzyme
present in
hepatocytes (liver cells). When a cell is damaged, it leaks this enzyme
into the blood, where it is measured. ALT rises dramatically in acute liver
damage, such as
viral hepatitis or
paracetamol (acetaminophen) overdose. Elevations are often measured in
multiples of the upper limit of normal (ULN). The reference range is 15-45 U/L
in most laboratories.
Aspartate transaminase (AST) also called Serum Glutamic Oxaloacetic
Transaminase (SGOT) or aspartate aminotransferase (ASAT) is similar to ALT in
that it is another enzyme associated with liver parenchymal cells. It is
raised in acute liver damage, but is also present in red cells, and cardiac
and skeletal muscle and is therefore not specific to the liver. The ratio of
AST to ALT is sometimes useful in differentiating between causes of liver
damage: In resource-poor settings, the AST is more frequently
available than the ALT, because it is a cheaper assay.
Alkaline phosphatase (ALP) is an enzyme in the cells lining the
biliary ducts of the liver. ALP levels in plasma will rise with large bile
duct obstruction, intrahepatic
cholestasis or infiltrative diseases of the liver. ALP is also present in
bone and
placental
tissue, so it is higher in growing children (as their bones are being
remodelled). The reference range is usually 30-120 U/L.
Bilirubin
is a breakdown product of
heme (a part of
haemoglobin in red blood cells). The liver is responsible for clearing the
blood of bilirubin. It does this by the following mechanism: bilirubin is
taken up into
hepatocytes, conjugated (modified to make it water-soluble), and
secreted into the
bile, which is excreted into the intestine. Liver function tests typically measure Total
bilirubin (TBIL) and Direct bilirubin (a.k.a. conjugated bilirubin,
CB). Indirect bilirubin (a.k.a. unconjugated bilirubin, UCB) is
obtained by subtracting direct bilirubin from total bilirubin. Increased total bilirubin causes jaundice, and can
signal a number of problems: 1. Increased bilirubin production. This can be
due to a number of causes, including hemolytic anemias and internal
hemorrhage. 2. Problems with the liver, which are reflected as
deficiencies in bilirubin metabolism (e.g. reduced hepatocyte uptake,
impaired conjugation of bilirubin, and reduced hepatocyte secretion of
bilirubin). Some examples would be cirrhosis and viral hepatitis. 3. Obstruction of the bile ducts, reflected as
deficiencies in bilirubin excretion. (Obstruction can be located either
within the liver or outside the liver.) The diagnosis is narrowed down further by looking at
the levels of direct bilirubin. If direct (i.e. conjugated) bilirubin is
normal, then the problem is an excess of unconjugated bilirubin, and the
location of the problem is upstream of bilirubin excretion. Anemia, viral
hepatitis, or cirrhosis can be suspected. If direct bilirubin is elevated,
then the liver is conjugating bilirubin normally, but is not able to excrete
it. Bile duct obstruction by gallstones or cancer should be suspected. Although reasonably specific to the liver and a more
sensitive marker for cholestatic damage than ALP,
Gamma glutamyl transpeptidase (GGT) may be elevated with even minor,
sub-clinical levels of liver dysfunction. It can also be helpful in
identifying the cause of an isolated elevation in ALP. GGT is raised in
alcohol toxicity (acute and chronic). 5'NTD is another test specific for cholestasis or
damage to the intra or extrahepatic biliary system, and in some laboratories,
is used as a substitute for GGT for ascertaining whether an elevated ALP is of
biliary or extra-biliary origin. The liver is responsible for the production of
coagulation factors. The
international normalized ratio (INR) measures the speed of a particular
pathway of coagulation, comparing it to normal. If the INR is increased, it
means it is taking longer than usual for blood to clot. The INR will only be
increased if the liver is so damaged that synthesis of
vitamin K-dependent
coagulation factors has been impaired: it is not a sensitive measure of liver
function. It is very important to normalize the INR before
operating on people with liver problems (usually by transfusion with blood
plasma containing the deficient factors) as they could bleed excessively. The liver's ability to produce glucose (gluconeogenesis)
is usually the last function to be lost in the setting of fulminant liver
failure. HELLP syndrome is a life-threatening complication of
pre-eclampsia. Both conditions occur during the latter stages of
pregnancy,
or sometimes after
childbirth. HELLP
is an abbreviation of the main findings: [hide]
Often, a patient who develops HELLP syndrome has already been followed
up for
pregnancy-induced hypertension (gestational hypertension), or is
suspected to develop
pre-eclampsia (high blood pressure and
proteinuria). Up to 8% of all cases present after delivery. There is gradual but marked onset of
headaches
(30%), blurred vision,
malaise
(90%), nausea/vomiting
(30%), "band pain" around the upper
abdomen
(65%) and tingling in the extremities.
Oedema may
occur but its absence does not exclude HELLP syndrome.
Arterial hypertension is a diagnostic requirement, but may be mild.
Rupture of the liver capsule and a resultant
hematoma
may occur. If the patient gets a
seizure or
coma, the
condition has progressed into full-blown
eclampsia. Patients who present symptoms of HELLP can be misdiagnosed in the early
stages, increasing the risk of liver failure and morbidity (Padden, 1999). In a patient with possible HELLP syndrome, a batch of
blood
tests is performed: a
full blood count,
liver
enzymes,
renal function and
electrolytes and
coagulation studies. Often,
fibrin
degradation products (FDPs) are determined, which can be elevated.
Lactate dehydrogenase is a marker of hemolysis and is elevated (>600
U/liter).
Proteinuria is present but can be mild. The
platelet count has been found to be moderately predictive of severity:
under 50 million/L is class I (severe), between 50 and 100 is class II
(moderately severe) and >100 is class III (mild). This system is termed the
Mississippi classification (Martin et al 1990). The exact cause of HELLP is unknown, but general activation of the
coagulation cascade is considered the main underlying problem. Fibrin forms
crosslinked networks in the small
blood
vessels. This leads to a
microangiopathic hemolytic anemia: the mesh causes destruction of
red blood cells as if they were being forced through a strainer.
Additionally,
platelets are consumed. As the
liver appears
to be the main site of this process, downstream liver cells suffer
ischemia,
leading to periportal necrosis. Other organs can be similarly affected. HELLP
syndrome leads to a variant form of
disseminated intravascular coagulation (DIC), leading to paradoxical
bleeding,
which can make emergency surgery a serious challenge. The only effective treatment is delivery of the baby, preferably by
cesarean section. Several medications have been investigated for the
treatment of HELLP syndrome, but evidence is conflicting as to whether
magnesium sulfate decreases the risk of seizures and progress to eclampsia.
The DIC is treated with
fresh frozen plasma to replenish the coagulation proteins, and the
anemia may
require
blood transfusion. In mild cases,
corticosteroids and
antihypertensives (labetalol,
hydralazine,
nifedipine) may be sufficient. Intravenous fluids are generally required. Its incidence is reported as 0.2-0.6% of all pregnancies. Of women with
(pre)eclampsia, 4-12% also develop signs of a "superimposed" HELLP syndrome.
Mortality is 7-35% and perinatal mortality of the child may be up to 40%.
HELLP usually begins after the third trimester, and usually in Caucasian women
over the age of 25. (Padden, 1999.) Rarely, cases have been reported as early
as 23 weeks gestation. HELLP syndrome was identified as a distinct clinical entity (as opposed
to severe preeclampsia) by Dr Louis Weinstein in 1982. HELLP syndrome is a life-threatening complication of
pre-eclampsia. Both conditions occur during the latter stages of
pregnancy, or sometimes after
childbirth. HELLP is an abbreviation of the main findings: Often, a patient who develops HELLP syndrome has already been followed
up for
pregnancy-induced hypertension (gestational hypertension), or
is suspected to develop
pre-eclampsia (high blood pressure and
proteinuria). Up to 8% of all cases present after delivery. There is gradual but marked onset of
headaches (30%), blurred vision,
malaise (90%),
nausea/vomiting (30%), "band pain" around the upper
abdomen (65%) and tingling in the extremities.
Oedema may occur but its absence does not exclude HELLP syndrome.
Arterial hypertension is a diagnostic requirement, but may be mild.
Rupture of the liver capsule and a resultant
hematoma may occur. If the patient gets a
seizure or
coma, the condition has progressed into full-blown
eclampsia. Patients who present symptoms of HELLP can be misdiagnosed in the early
stages, increasing the risk of liver failure and morbidity (Padden, 1999). In a patient with possible HELLP syndrome, a batch of
blood tests is performed: a
full blood count,
liver enzymes,
renal function and
electrolytes and
coagulation studies. Often,
fibrin degradation products (FDPs) are determined, which can be
elevated.
Lactate dehydrogenase is a marker of hemolysis and is elevated (>600
U/liter).
Proteinuria is present but can be mild. The
platelet count has been found to be moderately predictive of severity:
under 50 million/L is class I (severe), between 50 and 100 is class II
(moderately severe) and >100 is class III (mild). This system is termed
the Mississippi classification (Martin et al 1990). The exact cause of HELLP is unknown, but general activation of the
coagulation cascade is considered the main underlying problem. Fibrin
forms crosslinked networks in the small
blood vessels. This leads to a
microangiopathic hemolytic anemia: the mesh causes destruction of
red blood cells as if they were being forced through a strainer.
Additionally,
platelets are consumed. As the
liver appears to be the main site of this process, downstream liver
cells suffer
ischemia, leading to periportal necrosis. Other organs can be
similarly affected. HELLP syndrome leads to a variant form of
disseminated intravascular coagulation (DIC), leading to paradoxical
bleeding, which can make emergency surgery a serious challenge. The only effective treatment is delivery of the baby, preferably by
cesarean section. Several medications have been investigated for the
treatment of HELLP syndrome, but evidence is conflicting as to whether
magnesium sulfate decreases the risk of seizures and progress to
eclampsia. The DIC is treated with
fresh frozen plasma to replenish the coagulation proteins, and the
anemia may require
blood transfusion. In mild cases,
corticosteroids and
antihypertensives (labetalol,
hydralazine,
nifedipine) may be sufficient. Intravenous fluids are generally
required. Its incidence is reported as 0.2-0.6% of all pregnancies. Of women with
(pre)eclampsia, 4-12% also develop signs of a "superimposed" HELLP
syndrome. Mortality is 7-35% and perinatal mortality of the child may be
up to 40%. HELLP usually begins after the third trimester, and usually in
Caucasian women over the age of 25. (Padden, 1999.) Rarely, cases have
been reported as early as 23 weeks gestation. HELLP syndrome was identified as a distinct clinical entity (as opposed
to severe preeclampsia) by Dr Louis Weinstein in 1982. The liver produces most of the
plasma
proteins in the body making a measure of the amount of protein in the
blood useful. Reference range (60-80 g/L).
Albumin is a protein made specifically by the liver, and can be
measured cheaply and easily. It is the main constituent of total protein;
the remaining fraction is called
globulin (including e.g. the
immunoglobulins). Albumin levels are decreased in chronic liver
disease, such as
cirrhosis. It is also decreased in
nephrotic syndrome, where it is lost through the urine. Poor
nutrition or states of protein catabolism may also lead to
hypoalbuminaemia. The
half-life of albumin is approximately 20 days. Albumin is not
considered to be an especially useful marker of liver synthetic function,
coagulation factors (see below) are much more sensitive. The reference
range is 30-50 g/L. (3.0-5.0 g/dL)
Alanine transaminase (ALT), also called Serum Glutamic Pyruvic
Transaminase (SGPT) or Alanine aminotransferrase (ALAT) is an
enzyme present in
hepatocytes (liver cells). When a cell is damaged, it leaks this
enzyme into the blood, where it is measured. ALT rises dramatically in
acute liver damage, such as
viral hepatitis or
paracetamol (acetaminophen) overdose. Elevations are often measured in
multiples of the upper limit of normal (ULN). The reference range is 15-45
U/L in most laboratories.
Aspartate transaminase (AST) also called Serum Glutamic Oxaloacetic
Transaminase (SGOT) or aspartate aminotransferase (ASAT) is similar to ALT
in that it is another enzyme associated with liver parenchymal cells. It
is raised in acute liver damage, but is also present in red cells, and
cardiac and skeletal muscle and is therefore not specific to the liver.
The ratio of AST to ALT is sometimes useful in differentiating between
causes of liver damage: In resource-poor settings, the AST is more
frequently available than the ALT, because it is a cheaper assay.
Alkaline phosphatase (ALP) is an enzyme in the cells lining the
biliary ducts of the liver. ALP levels in plasma will rise with large
bile duct obstruction, intrahepatic
cholestasis or infiltrative diseases of the liver. ALP is also present
in
bone and
placental tissue, so it is higher in growing children (as their bones
are being remodelled). The reference range is usually 30-120 U/L.
Bilirubin is a breakdown product of
heme (a part of
hemoglobin in red blood cells). The liver is responsible for clearing
the blood of bilirubin. It does this by the following mechanism: bilirubin
is taken up into
hepatocytes, conjugated (modified to make it water-soluble),
and secreted into the
bile, which is excreted into the intestine. Liver function tests typically measure Total
bilirubin (TBIL) and Direct bilirubin (a.k.a. conjugated
bilirubin, CB). Indirect bilirubin (a.k.a. unconjugated bilirubin,
UCB) is obtained by subtracting direct bilirubin from total bilirubin. Increased total bilirubin causes jaundice, and
can signal a number of problems: 1. Increased bilirubin production. This
can be due to a number of causes, including hemolytic anemias and internal
hemorrhage. 2. Problems with the liver, which are reflected
as deficiencies in bilirubin metabolism (e.g. reduced hepatocyte
uptake, impaired conjugation of bilirubin, and reduced hepatocyte
secretion of bilirubin). Some examples would be cirrhosis and viral
hepatitis. 3. Obstruction of the bile ducts, reflected as
deficiencies in bilirubin excretion. (Obstruction can be located
either within the liver or outside the liver.) The diagnosis is narrowed down further by looking
at the levels of direct bilirubin. If direct (i.e. conjugated) bilirubin
is normal, then the problem is an excess of unconjugated bilirubin, and
the location of the problem is upstream of bilirubin excretion. Anemia,
viral hepatitis, or cirrhosis can be suspected. If direct bilirubin is
elevated, then the liver is conjugating bilirubin normally, but is not
able to excrete it. Bile duct obstruction by gallstones or cancer should
be suspected. Although reasonably specific to the liver and a
more sensitive marker for cholestatic damage than ALP,
Gamma glutamyl transpeptidase (GGT) may be elevated with even minor,
sub-clinical levels of liver dysfunction. It can also be helpful in
identifying the cause of an isolated elevation in ALP. GGT is raised in
alcohol toxicity (acute and chronic). 5'NTD is another test specific for cholestasis or
damage to the intra or extrahepatic biliary system, and in some
laboratories, is used as a substitute for GGT for ascertaining whether an
elevated ALP is of biliary or extra-biliary origin. The liver is responsible for the production of
coagulation factors. The
international normalized ratio (INR) measures the speed of a
particular pathway of coagulation, comparing it to normal. If the INR is
increased, it means it is taking longer than usual for blood to clot. The
INR will only be increased if the liver is so damaged that synthesis of
vitamin K-dependent coagulation factors has been impaired: it is not a
sensitive measure of liver function. It is very important to normalize the INR before
operating on people with liver problems (usually by transfusion with blood
plasma containing the deficient factors) as they could bleed excessively. The liver's ability to produce glucose (gluconeogenesis)
is usually the last function to be lost in the setting of fulminant liver
failure. This entry is from Wikipedia, the
leading user-contributed encyclopedia. It may not have been reviewed by
professional editors (see
full disclaimer) During its premarketing assessment,
multiple doses of ZOLOFT were
administered to over 4000 adult
subjects as of February 18, 2000. The conditions and duration of
exposure to ZOLOFT varied
greatly, and included (in overlapping categories)
clinical
pharmacology studies,
open and double-blind studies,
uncontrolled and controlled studies,
inpatient and
outpatient studies,
fixed-dose and titration studies, and studies for
multiple indications,
including major depressive disorder, OCD,
panic disorder, PTSD, PMDD and
social anxiety disorder.
Untoward events associated with this
exposure were recorded by
clinical investigators using
terminology of their own
choosing. Consequently, it is not possible to provide a meaningful estimate
of the proportion of individuals experiencing adverse events without first
grouping similar types of
untoward events into a smaller
number of standardized event categories. In the tabulations that follow, a World Health
Organization dictionary of terminology has been used to classify reported
adverse events. The frequencies presented, therefore, represent the
proportion of the over 4000 adult
individuals exposed to multiple
doses of ZOLOFT who experienced a treatment-emergent adverse event of the
type cited on at least one
occasion while receiving ZOLOFT. An
event was considered treatment-emergent if it occurred for the first
time or worsened while receiving
therapy following
baseline evaluation. It is
important to emphasize that events reported during
therapy were not necessarily
caused by it. The prescriber should be aware that the figures in
the tables and tabulations cannot be used to predict the
incidence of
side effects in the course of
usual medical
practice where
patient characteristics and
other factors differ from those that prevailed in the
clinical trials. Similarly,
the cited frequencies cannot be compared with figures obtained from other
clinical investigations
involving different treatments, uses, and investigators. The cited figures,
however, do provide the prescribing
physician with some
basis for estimating the
relative contribution of drug and
nondrug factors to the side
effect incidence
rate in the
population studied.
Incidence in Placebo-Controlled Trials¾Table 1
enumerates the most common treatment-emergent adverse events associated with
the use of ZOLOFT (incidence of at least 5% for ZOLOFT and at least twice
that for placebo within at
least one of the indications) for the
treatment of adult patients
with major depressive disorder/other*, OCD,
panic disorder, PTSD, PMDD and
social anxiety
disorder in
placebo-controlled clinical
trials. Most patients in major depressive disorder/other*, OCD,
panic disorder, PTSD and social
anxiety disorder studies
received doses of 50 to 200 mg/day. Patients in the PMDD study with daily
dosing throughout the menstrual
cycle received doses of 50 to 150 mg/day, and in the PMDD study with
dosing during the luteal
phase of the menstrual
cycle received doses of 50 to
100 mg/day. Table 2 enumerates treatment-emergent adverse events that
occurred in 2% or more of adult
patients treated with ZOLOFT and with
incidence greater than
placebo who participated in
controlled clinical trials comparing ZOLOFT with
placebo in the
treatment of major
depressive disorder/other*, OCD,
panic disorder, PTSD, PMDD and social
anxiety disorder. Table 2
provides combined data for the pool
of studies that are provided separately by indication in Table 1.
TABLE 1 MOST COMMON TREATMENT-EMERGENT ADVERSE EVENTS:
INCIDENCE IN PLACEBO-CONTROLLED CLINICAL TRIALS (1)Primarily
ejaculatory delay.
Denominator used was for male
patients only (N=271 ZOLOFT major depressive disorder/other*; N=271
placebo major depressive
disorder/other*; N=296 ZOLOFT OCD; N=219
placebo OCD; N=216 ZOLOFT
panic disorder; N=134
placebo
panic disorder; N=130 ZOLOFT
PTSD; N=149 placebo PTSD; No
male patients in PMDD studies; N=205 ZOLOFT social
anxiety disorder; N=153
placebo social anxiety
disorder). *Major depressive
disorder and other
premarketing controlled trials. (2)The
luteal
phase and daily dosing PMDD
trials were not designed for making direct comparisons between the two
dosing regimens. Therefore, a comparison between the two dosing regimens of
the PMDD trials of incidence
rates shown in Table 1 should be avoided. TABLE 2 TREATMENT-EMERGENT ADVERSE EVENTS: INCIDENCE IN
PLACEBO-CONTROLLED CLINICAL TRIALS Percentage of Patients Reporting Event
Major Depressive Disorder/Other*, OCD, Panic Disorder, PTSD, PMDD and Social
Anxiety Disorder combined (1)Primarily
ejaculatory delay.
Denominator used was for male
patients only (N=1118 ZOLOFT; N=926 placebo). *Major depressive
disorder and other
premarketing controlled trials. **Included are events reported by at least 2% of
patients taking ZOLOFT except the following events, which had an
incidence on
placebo greater than or equal
to ZOLOFT: abdominal pain,
back pain, flatulence, malaise,
pain, pharyngitis, respiratory
disorder, upper respiratory
tract infection. Associated with Discontinuation in Placebo-Controlled
Clinical
Trials Table 3 lists the adverse events associated with
discontinuation of ZOLOFTÒ
(sertraline hydrochloride)
treatment (incidence at least twice that for placebo and at least 1% for
ZOLOFT in clinical trials) in
major depressive disorder/other*, OCD,
panic disorder, PTSD, PMDD and
social anxiety disorder.
TABLE 3 MOST COMMON ADVERSE EVENTS ASSOCIATED WITH
DISCONTINUATION IN PLACEBO-CONTROLLED CLINICAL TRIALS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||